Efficacy and safety of drug-eluting stents in patients with acute st-segment-elevation myocardial infarction: A Meta-Analysis of randomized controlled trials

Texas Heart Institute Journal

Volumn 37, Issue 5, 2010, Pages 516-524

  Hao, Pan Pan ^a   Chen, Yu Guo ^a   Wang, Xing Li ^b   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Angioplasty, transluminal, percutaneous coronary instrumentation methods; Coronary restenosis prevention control; Data interpretation, statistical; Disease free survival; Drug eluting stents adverse effects utilization; Metaanalysis; Myocardial infarction therapy; Randomized controlled trials as topic; Recurrence prevention and control; Stents adverse effects classification utilization; Treatment outcome

Indexed keywords

PACLITAXEL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE;

BARE METAL STENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; GENETIC HETEROGENEITY; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; REOPERATION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANGIOPLASTY, BALLOON, CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78449263571     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Boersma E; Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27(7):779-88.
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361(9351):13-20.
3. Pasceri V, Granatelli A, Pristipino C, Pelliccia F, Speciale G, Pironi B, et al. A randomized trial of a rapamycin-eluting stent in acute myocardial infarction: preliminary results [abstract]. Am J Cardiol 2003;92(Suppl 6A):1A.
4. Di Lorenzo E, Varricchio A, Lanzillo T, Sauro R, Cianciulli GM, Manganelli F, et al. Paclitaxel and sirolimus stent implantation in patients with acute myocardial infarction [abstract]. Circulation 2005;112(Suppl):U538.
5. Pittl U, Kaiser C, Brunner-La Rocca HP, Hunziker P, Linka AZ, Osswald S, et al. Safety and efficacy of drug eluting stents versus bare metal stents in primary angioplasty of patients with acute ST-elevation myocardial infarction-a prospective randomized study [abstract]. Eur Heart J 2006;27(Suppl):650.
6. Tierala I, Syvanne M, Kupari M, for the HAAMU-STENT study group. Comparison of paclitaxel-eluting with bare metal stents in acute myocardial infarction: the HAAMUSTENT study. Presented at the Transcatheter Cardiovascular Therapeutics 2006 Annual Symposium, 24 October 2006.
7. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355(11):1105-13.
8. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355(11):1093-104.
9. Gao H, Yan HB, Zhu XL, Li N, Ai H, Wang J, et al. Firebird sirolimus eluting stent versus bare mental [sic] stent in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl) 2007;120(10):863-7.
10. Diaz de la Llera LS, Ballesteros S, Nevado J, Fernandez M, Villa M, Sanchez A, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007;154(1):164.e1-6.
11. Chechi T, Vittori G, Biondi Zoccai GG, Vecchio S, Falchetti E, Spaziani G, et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 2007;20(4): 282-91.
12. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, et al. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 2007;49(19):1924-30.
13. Valgimigli M, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa inhibitor infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 2007;50(2):138-45.
14. Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Klovgaard L, Kaltoft A, et al. Drug-eluting versus bare metal stents in patients with ST-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008;118(11):1155-62.
15. van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! intervention study. J Am Coll Cardiol 2008;51(6):618-26.
16. Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angioplasty (PASEO) randomized trial. Am Heart J 2009;158(4):e43-50.
17. Hannan EL, Racz M, Walford G, Holmes DR, Jones RH, Sharma S, et al. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008;1(2):129-35.
18. Brodie BR, Stuckey T, Downey W, Humphrey A, Nussbaum M, Laurent S, et al. Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Catheter Cardiovasc Interv 2008;72(7):893-900.
19. Nienaber CA, Akin I, Schneider S, Senges J, Fetsch T, Tebbe U, et al. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry). Am J Cardiol 2009;104(10):1362-9.
20. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360(19): 1946-59.
21. Kukreja N, Onuma Y, Garcia-Garcia H, Daemen J, van Domburg R, Serruys PW. Primary percutaneous coronary intervention for acute myocardial infarction: long-term outcome after bare metal and drug-eluting stent implantation. Circ Cardiovasc Interv 2008;1(2):103-10.
22. Daemen J, Tanimoto S, Garcia-Garcia HM, Kukreja N, van de Sande M, Sianos G, et al. Comparison of three-year clinical outcome of sirolimus and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007;99(8):1027-32.
23. Gurvitch R, Lefkovits J, Warren RJ, Duffy SJ, Clark DJ, Eccleston D, et al. Clinical outcomes of drug-eluting stent use in patients with ST elevation myocardial infarction. Int J Cardiol 2010;143(3):283-8.
24. Patel MR, Pfisterer ME, Betriu A, Widmisky P, Holmes DR Jr, O'Neill WW, et al. Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). Am J Cardiol 2009;103(2):181-6.
25. Steg PG, Fox KA, Eagle KA, Furman M, Van de Werf F, Montalescot G, et al. Mortality following placement of drugeluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 2009;30(3):321-9.
26. Leibundgut G, Nietlispach F, Pittl U, Brunner-La Rocca H, Kaiser CA, Pfisterer ME. Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina-comparison of the effects of drug-eluting versus bare-metal stents. Am Heart J 2009;158 (2):271-6.
27. Drug-eluting stents for the treatment of coronary artery disease. London: National Institute for Health and Clinical Excellence (NICE). 2008 Jul [cited 2010 Aug 4]. Available at http://www.guideline.gov/summary/summary.aspx?doc_id=12971&nbr=6680&=15.
28. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17(1):1-12.
29. Pasceri V, Patti G, Speciale G, Pristipino C, Richichi G, Di Sciascio G. Meta-analysis of clinical trials on use of drugeluting stents for treatment of acute myocardial infarction. Am Heart J 2007;153(5):749-54.
30. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28(22):2706-13.
31. De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol 2009;133(2):213-2.
32. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26(8):804-47.
33. BautersC,DelomezM,VanBelleE,McFaddenE,Lablanche JM, Bertrand ME. Angiographically documented late reoc-clusion after successful coronary angioplasty of an infarct-related lesion is a powerful predictor of long-term mortality. Circulation 1999;99(17):2243-50.
34. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115(8):1051-8.
35. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98(3):352-6.
36. Inoue T, Sohma R, Miyazaki T, Iwasaki Y, Yaguchi I, Mo-rooka S. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000;86 (10):1057-62.
37. Shin DI, Kim PJ, Seung KB, Kim DB, Kim MJ, Chang K, et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 2007;48(5):553-67.
38. Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention 2008;4 Suppl C:C7-10.